Literature DB >> 18335317

Single-cell tumor dormancy model of uveal melanoma.

Patrick T Logan1, Bruno F Fernandes, Sebastian Di Cesare, Jean-Claude A Marshall, Shawn C Maloney, Miguel N Burnier.   

Abstract

BACKGROUND: Ocular melanoma is easily treated by the removal of the eye or through plaque radiotherapy. However, after removal or control of the primary tumor, patients can develop fatal liver metastases up to 20 years later. It has been reported that difficulties in imaging single cells and the propensity for tumor cells to replicate rapidly in animal models account for the deficit of single-cell tumor dormancy models.
METHODS: In this paper, we performed two animal experiments using green fluorescent-labeled uveal melanoma cells in nude mice. Cells were injected via tail-vein and the experiments ran 20 and 42 days, respectively. Labeled cells were imaged in vivo via skin-flap and epifluorescent microscopy.
RESULTS: The first experiment exemplified the feasibility of a single-cell tumor dormancy model; cells were present in multiple organs post-injection, but persisted solely in the liver for the duration of the experiment. The second experiment, demonstrating the presence and viability of these single, metastatic seeds 6 weeks after injection.
CONCLUSION: Due to the inherent difficulties in establishing single-celled tumor dormancy models, few exist. In this paper, we have successfully developed a single-cell dormancy model of uveal melanoma, a disease that, in patients, epitomizes tumor dormancy. This model has the potential to reveal the mechanisms behind dormancy, identify patients at high risk for metastatic development, and develop new serum biomarkers for micrometastasis detection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18335317     DOI: 10.1007/s10585-008-9158-2

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  36 in total

1.  Bioluminescent indicators in living mammals.

Authors:  P R Contag; I N Olomu; D K Stevenson; C H Contag
Journal:  Nat Med       Date:  1998-02       Impact factor: 53.440

Review 2.  New treatment modalities for uveal melanoma.

Authors:  P De Potter; C L Shields; J A Shields
Journal:  Curr Opin Ophthalmol       Date:  1996-06       Impact factor: 3.761

3.  The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma.

Authors:  Jean-Claude A Marshall; Bruno F Fernandes; Sebastian Di Cesare; Shawn C Maloney; Patrick T Logan; Emilia Antecka; Miguel N Burnier
Journal:  Carcinogenesis       Date:  2007-04-13       Impact factor: 4.944

4.  Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment.

Authors:  S Eskelin; S Pyrhönen; P Summanen; M Hahka-Kemppinen; T Kivelä
Journal:  Ophthalmology       Date:  2000-08       Impact factor: 12.079

5.  Hamster Greene melanoma implanted in the anterior chamber of a rabbit eye: a reliable tumor model?

Authors:  T J Römer; J L van Delft; D de Wolff-Rouendaal; M J Jager
Journal:  Ophthalmic Res       Date:  1992       Impact factor: 2.892

6.  New colorimetric cytotoxicity assay for anticancer-drug screening.

Authors:  P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

7.  Very long-term prognosis of patients with malignant uveal melanoma.

Authors:  Emma Kujala; Teemu Mäkitie; Tero Kivelä
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-11       Impact factor: 4.799

8.  Survival rates with uveal melanoma in the United States: 1973-1997.

Authors:  Arun D Singh; Allan Topham
Journal:  Ophthalmology       Date:  2003-05       Impact factor: 12.079

9.  Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases.

Authors:  George N Naumov; Jason L Townson; Ian C MacDonald; Sylvia M Wilson; Vivien H C Bramwell; Alan C Groom; Ann F Chambers
Journal:  Breast Cancer Res Treat       Date:  2003-12       Impact factor: 4.872

10.  Establishment and characterization of an uveal-melanoma cell line.

Authors:  I De Waard-Siebinga; D J Blom; M Griffioen; P I Schrier; E Hoogendoorn; G Beverstock; E H Danen; M J Jager
Journal:  Int J Cancer       Date:  1995-07-17       Impact factor: 7.396

View more
  10 in total

Review 1.  Dormancy of metastatic melanoma.

Authors:  Liliana Ossowski; Julio A Aguirre-Ghiso
Journal:  Pigment Cell Melanoma Res       Date:  2009-10-19       Impact factor: 4.693

2.  The synthetic triterpenoid CDDO-Imidazolide suppresses experimental liver metastasis.

Authors:  Jason L Townson; Ian C Macdonald; Karen T Liby; Lisa Mackenzie; David W Dales; Benjamin D Hedley; Paula J Foster; Michael B Sporn; Ann F Chambers
Journal:  Clin Exp Metastasis       Date:  2011-01-15       Impact factor: 5.150

3.  Progression of ocular melanoma metastasis to the liver: the 2012 Zimmerman lecture.

Authors:  Hans E Grossniklaus
Journal:  JAMA Ophthalmol       Date:  2013-04       Impact factor: 7.389

4.  Tumour Expression of Histone Deacetylases in Uveal Melanoma.

Authors:  Louis Levinzon; Michele Madigan; Vuong Nguyen; Enisa Hasic; Max Conway; Svetlana Cherepanoff
Journal:  Ocul Oncol Pathol       Date:  2018-09-18

5.  Serum vascular endothelial growth factor (VEGF) levels correlate with number and location of micrometastases in a murine model of uveal melanoma.

Authors:  Michelle B Crosby; Hua Yang; Weiqing Gao; Lane Zhang; Hans E Grossniklaus
Journal:  Br J Ophthalmol       Date:  2010-09-06       Impact factor: 4.638

Review 6.  Melanoma and the Unfolded Protein Response.

Authors:  Erin K Sykes; Swetlana Mactier; Richard I Christopherson
Journal:  Cancers (Basel)       Date:  2016-02-27       Impact factor: 6.639

Review 7.  Role of Natural Killer Cells in Uveal Melanoma.

Authors:  Asad Javed; Mohammed Milhem
Journal:  Cancers (Basel)       Date:  2020-12-09       Impact factor: 6.639

8.  Irreversible electroporation of human primary uveal melanoma in enucleated eyes.

Authors:  Yossi Mandel; Shlomi Laufer; Michael Belkin; Boris Rubinsky; Jacob Pe'er; Shahar Frenkel
Journal:  PLoS One       Date:  2013-09-05       Impact factor: 3.240

9.  Decoding melanoma metastasis.

Authors:  William E Damsky; Lara E Rosenbaum; Marcus Bosenberg
Journal:  Cancers (Basel)       Date:  2010-12-30       Impact factor: 6.639

10.  Melanoma dormancy in a mouse model is linked to GILZ/FOXO3A-dependent quiescence of disseminated stem-like cells.

Authors:  Yasmine Touil; Pascaline Segard; Pauline Ostyn; Severine Begard; Caroline Aspord; Raja El Machhour; Bernadette Masselot; Jerome Vandomme; Pilar Flamenco; Thierry Idziorek; Martin Figeac; Pierre Formstecher; Bruno Quesnel; Renata Polakowska
Journal:  Sci Rep       Date:  2016-07-28       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.